In short
IOMX-0675 is an investigational monoclonal antibody that targets the immune checkpoint receptors LILRB1 and LILRB2. It is being studied in a Phase 1 trial with 110 participants who have advanced or metastatic solid tumors that have already been treated. The trial tests IOMX-0675 alone and in combination with pembrolizumab (Keytruda).
Key points
- IOMX-0675 is an investigational antibody targeting LILRB1 and LILRB2, receptors involved in tumor immune evasion.
- The ongoing Phase 1 trial enrolls 110 participants with advanced or metastatic solid tumors.
- The trial tests IOMX-0675 alone and in combination with pembrolizumab.
- The main goal is to find the recommended Phase 2 dose and assess safety.
- IOMX-0675 is given as an intravenous infusion.
- The trial is currently authorised in the EU.
What is IOMX-0675?
IOMX-0675 is an investigational monoclonal immunoglobulin G1 (IgG1) antibody. It is a protein-based substance developed by IOMX Therapeutics AG. The substance has no marketing authorisation in the product records, meaning it is not yet an approved medicine. It is classified in the therapeutic area of neoplasms, which are abnormal growths of tissue that can be cancerous.
How does IOMX-0675 work?
IOMX-0675 targets two receptors called LILRB1 (also known as ILT2) and LILRB2 (also known as ILT4). These receptors belong to the leukocyte immunoglobulin-like receptor (LILR) family and play a key role in tumor immune evasion, which is the ability of cancer cells to hide from the immune system. LILRB1 and LILRB2 are highly expressed on tumor-infiltrating myeloid cells, a type of immune cell found inside tumors, with LILRB1 also found on lymphoid cells. By blocking these receptors, IOMX-0675 is designed to reprogram immunosuppressive macrophages, restoring the activity of immune cells against the tumor.
Which conditions is IOMX-0675 studied for?
- Advanced or metastatic solid tumors — cancers that have spread from where they started to other parts of the body and have already been treated.
How is IOMX-0675 given?
IOMX-0675 is given as an intravenous infusion, meaning it is delivered directly into a vein over a period of time. In the current trial, it is administered at a dose of 1800 mg.
What do the clinical trials show?
One Phase 1 trial is currently authorised for IOMX-0675. The trial, called LIMNOS, enrolls 110 participants with advanced or metastatic solid tumors that have already been treated. It tests IOMX-0675 alone and in combination with pembrolizumab, an approved immunotherapy. The primary goal is to identify the recommended Phase 2 dose (RP2D) of IOMX-0675, both as a single agent and in combination with pembrolizumab. Researchers also measure dose-limiting toxicities, treatment-related adverse events, and pharmacokinetic parameters such as how much of the drug stays in the blood over time (AUC) and its half-life (t½). The trial also evaluates maximum receptor occupancy and biomarker activity.
What side effects are known?
The available sources do not provide a detailed list of side effects for IOMX-0675. The Phase 1 trial is designed to assess the type, incidence, and severity of treatment-related adverse events according to the NCI CTCAE version 5.0, a standard scale for reporting side effects in cancer trials.